Bipolar Disorder

Biomarkers for mental disorders is a field whose time has come. Optimists will say within a few years, pessimists might say a decade or beyond.

The petition to reform DSM-5 continues to gain momentum. In its first full week, more than 2300 people have already expressed their disapproval of the DSM-5 proposals and their desire to see dramatic changes. And the numbers are growing each day.

On the BSDS what score range indicates that there is a moderate probability of bipolar spectrum disorder? During euthymia, bipolar patients may have chronic impulsivity that predisposes them to aggression-especially those with comorbid features of which disorder? These questions and more in this quiz.

In Part 3 of this 3-part series, Dr Dilsaver discusses dichotomization versus a continuum model and concerns that bipolar disorders are over-diagnosed.

A recent front page story by Shari Roan in the Los Angeles Times explores the heated controversy over the DSM-5 proposal to include a Disruptive Mood Dysregulation Disorder (DMDD) in DSM-5. I very much oppose the inclusion of this new "disorder."

I do not hear loud applause for our current antidepressant armamentarium. I believe I hear the sound of one hand clapping.

Increased activity of the enzyme phospholipase A2 (PLA2) has been documented in schizophrenia and is now reported to occur in patients with temporal lobe epilepsy . . .

On the wide range of symptoms in schizophrenia, including alterations of the dopaminergic and/or glutamatergic systems, abnormal neurodevelopment, and the theory of immune system imbalance.

An initiative from the BRIDGE study group has determined that approximately half of patients presenting with a depressive episode are mistakenly diagnosed with unipolar major depression.

Several available agents in addition to methylene blue are being investigated for bipolar disorder and were in a in a recent review.

A study presented by Canadian investigators at the 24th Congress of the European College of Neuropsychopharmacology (ECNP) in Paris, September 5 evaluated whether methylene blue can reduce residual symptoms of depression and mania in bipolar disorder.

Addressing the Underlying Causes of Treatment Resistance

Treatment of anxiety can be a challenge, since the mainstay of treatment may adversely affect the course of bipolar disorder.

Regretfully, if we are to judge the progress of DSM-5 by the incoherence of a recent commentary by the Chair and Vice-chair of the DSM-5 Task Force, we have a lot to worry about.

Hoarding has broad-reaching implications, including a substantial public health burden linked to occupational impairment, poor physical health, and demand for social services.

It is our responsibility as psychiatrists to educate the media and the public in general.

Dear Mrs. -- You have asked me about the cause of your mood disorder, and whether it is due to a "chemical imbalance."

I was ready. In my mind I rehearsed agreeable sermons about diet, exercise, and MMR vaccines I’d use to shepherd my courteous new patients to wellness. It’s like I wanted to replace my memories of psychiatric patients with the most wholesome medical facts.

Newly developed blood tests for schizophrenia and for depression designed to augment current diagnostic approaches have attracted increased attention at recent major scientific meetings.

Polypharmacy has become so ubiquitous that more accidental overdoses are now caused by prescription drugs than by street drugs. The question naturally arises whether this almost routine use of multiple psychotropic medications make sense?

Martin Whiteley is an MP who represents Perth in the Australian parliament. He has been actively involved in mental health issues and succeeded in a crusade to curb what had been Perth's alarming overdiagnosis and overmedication of Attention Deficit Disorder (ADD).

The DSM-5 Scientific Review Group was the last hope for an eleventh hour DSM-5 save. This hope recently died.

The legend of the “chemical imbalance” should be consigned to the dust-bin of ill-informed and malicious caricatures.

During the past year, I have been involved as an expert witness for the defense in 14 SVP cases (tried in California, Washington, and Iowa). My role has been to clarify what is meant by the wording of the Paraphilia section in DSM-IV. And it certainly does badly need explaining.

Treatment resistance in bipolar disorder is clinically familiar but lacks a standard definition. Numerous evidence-based treatments exist for all phases of bipolar disorder, and these should be optimized and fully explored.

A balanced review of the safety and efficacy of ECT is needed, which does not mean weighing anecdotal reports of memory loss equally with systematically collected clinical data.

Many adolescents have taken to the Internet to discuss their struggles with psychiatric disorders not ordinarily diagnosed in persons under 18 years old (eg, bipolar disorder).

If telling patients they have “pre-clinical Alzheimer’s” or “MCI due to Alzheimer’s Disease”-absent effective treatment-produces more emotional suffering than it relieves, a difficult ethical question arises; namely, can such a disclosure be justified under the foundational principle of non-malfeasance?

In a decade-long study of antipsychotic prescribing for hospitalized children and adolescents, researchers found that antipsychotics were used in 44.3% of patients and were often prescribed for behavioral disorders, PTSD, and other anxiety disorders as well as psychotic disorders.

Researchers are developing a scale to measure a clinically identified emotional “trigger state” that puts individuals with suicidal ideation at increased risk of acting on their ideations.